Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia
Aim: Utilize the Bucher indirect treatment comparison (ITC) method to compare valbenazine and deutetrabenazine efficacy using clinical trial data. Methods: Outcomes included mean change from baseline in Abnormal Involuntary Movement Scale (AIMS) total score, AIMS response (≥50% improvement), clinical global impression of change response (score ≤2) and safety outcomes. Data were pooled by trial and dose; outcomes were analyzed at multiple time points. Results: ITC of AIMS score improvement significantly favored valbenazine 80 mg/day at 6 weeks versus deutetrabenazine 36 mg/day at 8 weeks, while valbenazine 40 mg/day was statistically similar to all doses of deutetrabenazine at all time points. No significant differences between drugs were found in AIMS and clinical global impression of change responses and safety outcomes. Conclusion: In this ITC of pooled trial data, valbenazine was generally favorable over deutetrabenazine, although dose titration and equivalency should be considered when interpreting results.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Journal of comparative effectiveness research - 8(2019), 13 vom: 20. Okt., Seite 1077-1088 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Aggarwal, Saurabh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
54K37P50KH |
|---|
| Anmerkungen: |
Date Completed 28.07.2020 Date Revised 28.07.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.2217/cer-2019-0059 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM300736126 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM300736126 | ||
| 003 | DE-627 | ||
| 005 | 20231225103155.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2217/cer-2019-0059 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1002.xml |
| 035 | |a (DE-627)NLM300736126 | ||
| 035 | |a (NLM)31464152 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Aggarwal, Saurabh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.07.2020 | ||
| 500 | |a Date Revised 28.07.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Aim: Utilize the Bucher indirect treatment comparison (ITC) method to compare valbenazine and deutetrabenazine efficacy using clinical trial data. Methods: Outcomes included mean change from baseline in Abnormal Involuntary Movement Scale (AIMS) total score, AIMS response (≥50% improvement), clinical global impression of change response (score ≤2) and safety outcomes. Data were pooled by trial and dose; outcomes were analyzed at multiple time points. Results: ITC of AIMS score improvement significantly favored valbenazine 80 mg/day at 6 weeks versus deutetrabenazine 36 mg/day at 8 weeks, while valbenazine 40 mg/day was statistically similar to all doses of deutetrabenazine at all time points. No significant differences between drugs were found in AIMS and clinical global impression of change responses and safety outcomes. Conclusion: In this ITC of pooled trial data, valbenazine was generally favorable over deutetrabenazine, although dose titration and equivalency should be considered when interpreting results | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a deutetrabenazine | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a indirect treatment comparison | |
| 650 | 4 | |a tardive dyskinesia | |
| 650 | 4 | |a valbenazine | |
| 650 | 7 | |a valbenazine |2 NLM | |
| 650 | 7 | |a 54K37P50KH |2 NLM | |
| 650 | 7 | |a Valine |2 NLM | |
| 650 | 7 | |a HG18B9YRS7 |2 NLM | |
| 650 | 7 | |a deutetrabenazine |2 NLM | |
| 650 | 7 | |a P341G6W9NB |2 NLM | |
| 650 | 7 | |a Tetrabenazine |2 NLM | |
| 650 | 7 | |a Z9O08YRN8O |2 NLM | |
| 700 | 1 | |a Serbin, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Yonan, Chuck |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of comparative effectiveness research |d 2012 |g 8(2019), 13 vom: 20. Okt., Seite 1077-1088 |w (DE-627)NLM218708033 |x 2042-6313 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2019 |g number:13 |g day:20 |g month:10 |g pages:1077-1088 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2217/cer-2019-0059 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2019 |e 13 |b 20 |c 10 |h 1077-1088 | ||